Strides Acquires 18 ANDAs From Pharmaceutics
Deal Also Includes Exclusive Rights To Levothyroxine Candidate
Strides has acquired 18 ANDAs from Pharmaceutics International, as well as exclusive marketing rights to a levothyroxine sodium candidate. Through this agreement, the Indian company plans to expand its niche offerings.
You may also be interested in...
Optimistic about the potential of repurposing its antivirals portfolio, Strides plans to soon begin bioequivalence studies for favipiravir, a molecule that has found favor as a COVID-19 therapy in a few countries. It also aims to introduce new products to fill the gap left by the withdrawal of ranitidine from the US market.
Strides' newly-appointed CEO, R Ananthanarayanan, sees no reason to change course as the firm's current strategy continues to yield positive results. The company posted a 29% increase in third-quarter revenues on the back of 62% growth in the US.
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.